You are here

Long-Acting Regimen of Cabotegravir and Rilpivirine Shows Sustained Virological Response and Good Tolerability in Patients with HIV

Injectable Combination Reduces Number of Annual Doses from 365 to 12

The injectable two-drug regimen of cabotegravir and rilpivirine (ViiV Healthcare, Brentford, England) could provide an alternative to daily tablets for patients with HIV, reducing the number of annual doses from 365 to 12.

Data from the LATTE-2 clinical trial showed durable treatment effects. At 160 weeks, 90% (n = 104/115) of patients who received the regimen every eight weeks and 83% (n = 95/115) of patients who received the regimen every four weeks remained virally suppressed. Patients in the oral comparator arm who switched to the injectable regimen at week 96 showed viral suppression rates of 97% (n = 33/34) and 100% (n = 10/10), respectively.

The most common adverse events included nasopharyngitis (38%), diarrhea (22%), and headache (22%). A majority of participants reported an injection-site reaction (ISR), 85% mild and 14% moderate, through week 160. Eighty-seven percent of ISRs resolved within seven days.

Sources: Seeking Alpha, October 29, 2018; ViiV Healthcare, October 30, 2018

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
Patient Access to Inhaler Use Data Could Improve Asthma Management
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens